ArticleBioprocess and biosystems engineering2025
Plasma substitute combination enhances in vitro expansion of blood cells by modulating redox status and signaling pathways.
Article in Bioprocess and biosystems engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma is the primary microenvironment, where red blood cells (RBCs) survive and function, with its components playing crucial roles in erythroid expansion and RBC functionality. This study aims to elucidate the relationship between the combination of critical components in plasma and the expansion and cell state of erythroid cells. Using Design of Experiment (DOE) methods, we screened and optimized the concentrations of plasma components that significantly impact the in vitro expansion of TF-1 cells. We identified a plasma substitute combination composed of hypoxanthine, dexamethasone, and vitamin B complex and, significantly enhancing TF-1 cell expansion in the serum-free medium supplemented with bovine serum albumin by 1012.41 folds, compared to 327.50 folds in the negative control. In addition, the proportion of CD34
Indexed as
Identifiers
40668367What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.